BYSI BeyondSpring, Inc.
Price Chart
Executive Summary
BeyondSpring reported Q1 2026 financial results showing a net loss from continuing operations of $2.4M, improved from a $2.6M loss in Q1 2025, with cash and short-term investments of $7.9M. The key event is the AACR 2026 data positioning Plinabulin as a potential backbone agent for ADC combination therapy and the advancement of SEED's first molecular glue degrader into clinical development, but the company has zero revenue and a limited cash runway.
Actionable Insight
Monitor for partnership or licensing deals around Plinabulin-ADC combinations given the AACR data, and watch for SEED Therapeutics financing or collaboration updates. The $7.9M cash position provides limited runway for a clinical-stage company with no revenue — a capital raise is likely within 12 months.
Key Facts
- Net loss from continuing operations was $2.4M for Q1 2026 vs $2.6M in Q1 2025
- Cash, cash equivalents, and short-term investments were $7.9M as of March 31, 2026
- R&D expenses increased to $1.1M from $0.9M year-over-year
- G&A expenses decreased to $1.1M from $1.7M year-over-year
- Discontinued operations (SEED) net loss was $4.3M vs net income of $3.8M in Q1 2025
- AACR 2026 data showed Plinabulin enhances efficacy and tolerability of ADC-based regimens
- SEED's ST-01156 RBM39 molecular glue degrader advanced into Phase 1 clinical development
- Zero revenue reported for both Q1 2026 and Q1 2025
Financial Impact
Net loss from continuing operations improved by $0.2M year-over-year; cash burn rate suggests ~8-9 months of runway at current spending levels
Risk Factors
- Limited cash runway of $7.9M with no revenue — likely need for near-term financing
- Discontinued operations (SEED) showing increased losses of $4.3M in Q1 2026
- Clinical-stage pipeline with no approved products or near-term commercialization path
- Nasdaq continued listing requirements risk given negative shareholders' equity of $30.4M
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293842 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
5d ago
|
8-K
| $1.71 $1.71 | · 0.00% | ▲ +2.60% | $1.70 (−0.58%) |
|
Jun 2, 2026
7d ago
|
Press Release
| $1.70 $1.74 | ▲ +2.35% | ▲ +3.07% | $1.70 (+0.00%) |
|
May 13, 2026
27d ago
|
8-K
| $1.45 $1.47 | ▲ +1.38% | ▲ +0.60% | $1.70 (+17.24%) |
|
May 13, 2026
27d ago
|
Press Release
| $1.45 $1.47 | ▲ +1.38% | ▲ +0.60% | $1.70 (+17.24%) |
|
Mar 25, 2026
10w ago
|
Press Release
| $1.61 $1.60 | ▼ −0.62% | ▲ +1.06% | $1.70 (+5.59%) |
|
Mar 25, 2026
10w ago
|
Press Release
| $1.68 $1.61 | ▼ −4.17% | ▼ −2.40% | $1.70 (+1.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access